Irreversible Electroporation-Assisted Resection for Locally Advanced Pancreas Cancer
- 15 February 2023
- journal article
- research article
- Published by SAGE Publications in Surgical Innovation
- Vol. 30 (3) , 332-339
Abstract
Background: A significant number of patients with advanced pancreatic cancer are unable to undergo resection due to vascular involvement. Irreversible electroporation (IRE) has shown promise in improving survival. This study sought to assess a novel IRE application whereby IRE was performed pre-resection to alter tissue plasticity and assist tumor removal from underlying vasculature when surgical excision was otherwise precluded. Methods: After multidisciplinary evaluation appropriate patients were consented for IRE therapy. All IRE cases were tracked prospectively using an institutional review board-approved database that was retrospectively queried for patients undergoing IRE-assisted resection (IRE-AR) for pancreatic adenocarcinoma located in the head/uncinate process. Patients who underwent other IRE therapy or had disease location elsewhere were excluded. Results: 5 patients met the study inclusion criteria with a mean tumor size of 3.2 cm (range 2.4-4.1 cm). Using IRE-AR median recurrence free survival was 10.6 months, with 21.6 month overall survival. The average comprehensive complication index score was 23.23. One patient had grade 3 [or higher] complications and there were no 90 day mortalities. Discussion: Employing a high-starting voltage for ablation along resection margins allows for resection when margins are anticipated to be positive. Patients with locally advanced pancreatic adenocarcinoma who underwent IRE-AR had promising outcomes. Conclusion: This study reports IRE-AR as a novel approach for resecting locally advanced pancreatic adenocarcinoma. A prospective trial of IRE-AR for inoperable pancreatic adenocarcinoma will provide additional data for the long-term application of this approach.Keywords
This publication has 23 references indexed in Scilit:
- Induction of rapid, reproducible hepatic ablations using next-generation, high frequency irreversible electroporation (H-FIRE) in vivoHPB, 2016
- Systematic Review of Resection Rates and Clinical Outcomes After FOLFIRINOX-Based Treatment in Patients with Locally Advanced Pancreatic CancerAnnals of Surgical Oncology, 2016
- Treatment of 200 Locally Advanced (Stage III) Pancreatic Adenocarcinoma Patients With Irreversible ElectroporationAnnals of Surgery, 2015
- Intra-operative Anesthesia Management in Patients Undergoing Surgical Irreversible Electroporation of the Pancreas, Liver, Kidney, and Retroperitoneal TumorsAnesthesiology and Pain Medicine, 2015
- Borderline and locally advanced pancreatic adenocarcinoma margin accentuation with intraoperative irreversible electroporationSurgery, 2014
- Electroporation-Based Technologies for Medicine: Principles, Applications, and ChallengesAnnual Review of Biomedical Engineering, 2014
- The Comprehensive Complication IndexAnnals of Surgery, 2013
- Irreversible Electroporation Therapy in the Management of Locally Advanced Pancreatic AdenocarcinomaJournal of the American College of Surgeons, 2012
- Irinotecan Plus Oxaliplatin and Leucovorin-Modulated Fluorouracil in Advanced Pancreatic Cancer—A Groupe Tumeurs Digestives of the Fédération Nationale des Centres de Lutte Contre le Cancer StudyJournal of Clinical Oncology, 2005
- Tissue Ablation with Irreversible ElectroporationAnnals of Biomedical Engineering, 2005